Definitions
Sorry, no definitions found. Check out and contribute to the discussion of this word!
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word non-squamous.
Examples
-
ZYBRESTAT is being evaluated in a Phase 2 study of patients with non-squamous non-small cell lung cancer and other clinical trials, including a recently completed Phase 2 study of ZYBRESTAT plus chemotherapy in patients with anaplastic thyroid cancer ATC.
unknown title 2011
-
ZYBRESTAT is being evaluated in studies of patients with anaplastic thyroid cancer, non-squamous non-small cell lung cancer, platinum-sensitive ovarian cancer and other clinical trials.
unknown title 2011
-
SATURN showed that Tarceva given as a maintenance therapy immediately after first-line chemotherapy significantly extended overall survival (OS) and significantly improved the time people with advanced NSCLC lived without the disease getting worse (progression-free survival, PFS), including people with either squamous or non-squamous NSCLC, compared with placebo.
Media Newswire media-newswire.com 2010
-
Other approved therapies, such as pemetrexed (Alimta ™) are indicated for non-squamous NSCLC only. 3
-
Enrolling up to 86 front-line, non-squamous NSCLC patients, this multi-center study is being conducted in the U.S. and internationally according to International Conference on
-
Improvement in median PFS was more pronounced in the pre-defined sub-group of patients with non-squamous histology (n = 117); median PFS was 18.9 weeks in the treatment arm versus 9.7 weeks in the control arm, which represents a 94% improvement.
-
Johns Hopkins University researchers demonstrated that miRview squamous correctly subclassified 95% of FNA cell block specimens and small biopsies originally diagnosed as poorly differentiated NSCLC into squamous and non-squamous cell carcinoma.
-
Improvement in median PFS was more pronounced in the pre-defined sub-group of patients with non-squamous histology (n = 117); median PFS was 18.9 weeks in the treatment arm versus 9.7 weeks in the control arm, which represents a 94% improvement.
-
This breakthrough will enable patients and physicians to benefit from a highly accurate diagnostic assay without having to undergo a more invasive procedure. miRview squamous is a molecular diagnostic test that measures the expression level of a single microRNA to accurately differentiate squamous from non-squamous NSCLC.
-
Improvement in median PFS was more pronounced in the pre-defined sub-group of patients with non-squamous histology (n = 117); median PFS was 18.9 weeks in the treatment arm versus 9.7 weeks in the control arm, which represents a 94% improvement.
THE MEDICAL NEWS Editors 2010
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.